Alagille Syndrome — designated ALGS, OMIM #118450 for the JAG1-related form and #610205 for the NOTCH2-related form, a multisystem developmental disorder defined by characteristic paucity of intrahepatic bile ducts producing neonatal and infantile cholestasis, in combination with congenital cardiac defects (most commonly peripheral pulmonary stenosis and tetralogy of Fallot), characteristic facial features, posterior embryotoxon and other anterior segment eye anomalies, and vertebral butterfly anomalies in the classic pentad described by Alagille and colleagues in 1969, affecting an estimated 1 in 30,000–70,000 live births with considerable underdiagnosis owing to variable expressivity — some patients presenting with severe neonatal liver failure requiring transplantation before age two while family members with the same pathogenic variant have only subtle cholestatic biochemical abnormalities — caused in approximately 94% of genotype-positive patients by heterozygous loss-of-function mutations in JAG1 encoding the Notch signaling ligand Jagged-1 (deletions identified in approximately 7% and point mutations in approximately 87% of JAG1-positive cases), and in approximately 3–5% of patients by heterozygous mutations in NOTCH2 encoding the Notch receptor for which Jagged-1 is a principal ligand during bile duct, cardiac, renal, and skeletal development; the hepatic phenotype is defined by intrahepatic bile duct paucity on liver biopsy (a bile duct-to-portal tract ratio below 0.5, compared to normal ratio approaching 1.0), cholestasis producing conjugated hyperbilirubinemia, elevated serum bile acids, elevated serum gamma-glutamyltransferase, and intensely pruritic xanthomata from hypercholesterolemia driven by obstructed bile flow, with liver disease severity spanning from mild persistent cholestatic biochemical abnormalities with histologically preserved hepatic architecture to progressive biliary cirrhosis with portal hypertension, esophageal varices, hypersplenism, and end-stage liver disease requiring hepatic transplantation — which is required in approximately 20–30% of ALGS patients, typically by early childhood; the cardiac phenotype present in more than 90% of patients encompasses peripheral pulmonary stenosis (most common) — which may be severe enough to require catheter-based or surgical intervention in infancy — tetralogy of Fallot (approximately 12–15% of patients), pulmonary atresia with ventricular septal defect, and other structural defects requiring pediatric cardiac surgery program management; the ophthalmological phenotype includes posterior embryotoxon (a prominent Schwalbe's line visible on slit-lamp examination, present in approximately 89% of ALGS patients but also in approximately 15% of the general population making it a non-specific finding in isolation), Axenfeld anomaly, Rieger anomaly, and rarely optic disc drusen contributing to visual field abnormality; the vertebral phenotype includes butterfly vertebrae from abnormal vertebral segmentation — most commonly at thoracic levels — which are generally asymptomatic but contribute to the radiographic diagnostic criteria; the renal phenotype — recognized increasingly as a significant contributor to morbidity in ALGS — includes renal tubular acidosis, renovascular hypertension from renal artery stenosis, renal cortical cysts, and Notch2-mediated glomerular abnormalities including focal segmental glomerulosclerosis; and the vascular phenotype — which generates the most severe non-hepatic morbidity — includes intracranial aneurysms, moyamoya disease, and vertebral artery abnormalities that produce intracranial hemorrhage and stroke in approximately 14% of ALGS patients — a catastrophic and often fatal complication that requires proactive neurovascular surveillance; management spans hepatology (ursodeoxycholic acid for cholestasis, rifampicin for pruritus, cholestyramine, ileal bile acid transport inhibitor maralixibat — recently approved specifically for ALGS-associated pruritus — and nutritional management of fat-soluble vitamin malabsorption), pediatric cardiac surgery and interventional cardiology for congenital cardiac defects, hepatic transplantation program coordination for end-stage liver disease, and neurovascular surveillance for intracranial vascular abnormalities.
Alagille Syndrome technology platforms — encompassing the genetic testing platforms where JAG1 and NOTCH2 sequencing with deletion/duplication analysis confirms molecular diagnosis and enables family cascade screening including prenatal diagnosis in families with established variants, the pediatric hepatology platforms managing neonatal and infantile cholestasis workup, ursodeoxycholic acid and rifampicin therapy, maralixibat administration for cholestasis-associated pruritus, nutritional support for fat-soluble vitamin malabsorption, and surveillance for biliary cirrhosis progression and hepatic transplantation indications, the pediatric cardiology and cardiac surgery platforms managing peripheral pulmonary stenosis, tetralogy of Fallot, and other congenital cardiac defects through catheter-based intervention, surgical repair, and longitudinal cardiology surveillance, the hepatic transplantation platforms coordinating pre-transplant evaluation, organ allocation, and post-transplant immunosuppression for the 20–30% of ALGS patients requiring liver replacement, the neurology and neurovascular imaging platforms managing the intracranial aneurysm and moyamoya vascular surveillance that is critical to preventing the 14% intracranial hemorrhage and stroke risk, the nephrology platforms managing renal tubular acidosis, renovascular hypertension, and glomerular disease, and the ophthalmology platforms performing the slit-lamp posterior embryotoxon assessment that contributes to diagnostic criteria and the annual eye surveillance recommended for ALGS patients — must maintain the availability and performance standards required by the neonatal cholestasis workup urgency, cardiac defect management obligations, liver transplantation platform continuity, neurovascular surveillance imperatives, nutritional monitoring requirements, and family cascade screening protocols that define modern ALGS management. This guide explains why Alagille Syndrome tech platforms need dedicated monitoring, what components to monitor, and how to build a monitoring strategy matched to the multisystem pediatric surveillance, hepatic transplantation management, neurovascular stroke prevention, congenital cardiac repair coordination, and family genetic screening that define modern care.
Why Alagille Syndrome Tech Platforms Require Specialized Monitoring Attention
Alagille Syndrome management is defined by several uniquely complex multisystem pediatric disease challenges: the neonatal cholestasis diagnostic urgency — conjugated hyperbilirubinemia in a neonate requires urgent workup to exclude biliary atresia (for which Kasai hepatoportoenterostomy within 60 days of birth is time-sensitive) while simultaneously evaluating for ALGS and other intrahepatic cholestasis conditions, placing diagnostic platform availability at a premium in the newborn period; the intracranial hemorrhage prevention imperative — the 14% intracranial hemorrhage risk from ALGS-associated intracranial aneurysms and moyamoya vasculopathy represents the most dangerous non-hepatic complication, and surveillance neurovascular imaging platforms must be available to execute the screening protocols that identify cerebrovascular pathology before it becomes symptomatic; the hepatic transplantation program coordination complexity — ALGS patients requiring liver transplantation face complex immunological and hemodynamic challenges from concurrent cardiac defects, and integrated hepatology, cardiac surgery, and transplant surgery coordination platforms must be available through the pre-transplant, peri-operative, and post-transplant course; and the pruritus management intensity — the intense cholestatic pruritus that characterizes ALGS impairs sleep, quality of life, and neurodevelopment in affected children, and maralixibat therapy monitoring platforms for the recently approved ileal bile acid transporter inhibitor must maintain availability to optimize dosing and response assessment.
Genetic testing platforms confirm JAG1 and NOTCH2 diagnosis and enable prenatal family screening. JAG1 sequencing with deletion/duplication analysis, NOTCH2 sequencing, and chromosomal microarray for 20p12 deletion detection provide the molecular diagnosis that enables family cascade testing and prenatal diagnosis in subsequent pregnancies. Monitor genetic testing platforms at 1-minute intervals during laboratory hours.
Pediatric hepatology platforms manage cholestasis, pruritus, and transplantation triage. Neonatal conjugated hyperbilirubinemia workup, ursodeoxycholic acid and rifampicin therapy management, maralixibat dosing and response monitoring, fat-soluble vitamin supplementation and level tracking, and liver biopsy interpretation for bile duct paucity confirmation require continuous clinical platform availability. Monitor hepatology platforms at 1-minute intervals during clinical hours.
Neurovascular imaging platforms screen for intracranial aneurysms and moyamoya disease. Brain MRI and MRA, CT angiography, and catheter angiography for definitive characterization of intracranial vascular abnormalities responsible for the 14% stroke and hemorrhage risk require reliable imaging platform availability across the ALGS surveillance schedule. Monitor neurovascular imaging platforms at 1-minute intervals during imaging hours.
Hepatic transplant platforms coordinate organ allocation and post-transplant management. ALGS patients with end-stage liver disease require integrated transplant platform availability for PELD/MELD score tracking, organ allocation queue management, pre-transplant cardiac surgery coordination for concurrent cardiac defects, and post-transplant immunosuppression monitoring. Monitor transplant platforms at 1-minute intervals during clinical hours, 24/7 for transplant coordination.
What to Monitor on an Alagille Syndrome Tech Platform
Genetic Testing — JAG1, NOTCH2, and Chromosomal Microarray Analysis
Monitor genetic testing referral records (clinical suspicion documentation — neonatal conjugated hyperbilirubinemia with intrahepatic bile duct paucity on liver biopsy, peripheral pulmonary stenosis or tetralogy of Fallot in a cholestatic infant, posterior embryotoxon on slit-lamp examination combined with hepatic and cardiac abnormalities, butterfly vertebrae on spinal radiograph in a child with chronic liver disease, ALGS pentad partial phenotype recognition, family history of ALGS or unexplained chronic liver disease, positive newborn screen for elevated bile acids or hyperbilirubinemia requiring workup), JAG1 sequencing records (comprehensive sequencing of all 26 exons and splice junctions — point mutation detection, small indel identification, variant classification as pathogenic/likely pathogenic/VUS, deletion/duplication analysis by MLPA for single and multi-exon deletions, chromosomal microarray for 20p12 deletions not detectable by sequencing alone), NOTCH2 sequencing records (NOTCH2 point mutations in JAG1-negative patients, NOTCH2-related ALGS with renal involvement and Alagille-like phenotype), family cascade genetic testing records (cascade testing of parents — one parent found to carry the variant in approximately 50–70% of cases attributing to intrafamilial de novo versus heritable variant, sibling and extended family testing where heritable variant identified, prenatal diagnosis by chorionic villus sampling or amniocentesis in subsequent pregnancies of confirmed carrier parents), and genetic counseling records (de novo versus heritable variant inheritance discussion, 50% recurrence risk for heritable variants, variable expressivity within families — affected parent with minimal phenotype whose child has severe liver disease counseling, prenatal diagnosis planning) at 1-minute intervals during laboratory hours. Alert immediately — JAG1 deletion/duplication analysis platform failures during the evaluation of a 6-week-old with persistent conjugated hyperbilirubinemia — when the pediatric gastroenterologist's differential includes biliary atresia requiring urgent surgical assessment, Alagille syndrome, progressive familial intrahepatic cholestasis, and other intrahepatic cholestasis conditions — delay the molecular confirmation that distinguishes ALGS (where Kasai hepatoportoenterostomy is not indicated) from biliary atresia (where Kasai hepatoportoenterostomy within 60 days of life is the life-saving intervention), a diagnostic distinction of immediate surgical urgency in a 6-week-old infant.
Pediatric Hepatology — Cholestasis, Pruritus, and Nutrition Management
Monitor cholestasis biochemical surveillance records (serial serum bilirubin — conjugated and unconjugated fractions, serum GGT as principal marker of cholestasis in ALGS, serum bile acids, alkaline phosphatase, aminotransferase levels tracking hepatocellular injury superimposed on cholestasis, cholesterol and triglycerides for xanthomatous hypercholesterolemia management), ursodeoxycholic acid records (UDCA dosing at 10–15 mg/kg/day, response monitoring through GGT and bilirubin trend, dose adjustment records), rifampicin records (rifampicin for cholestatic pruritus — cytochrome P450 induction mechanism, dose titration, liver function monitoring for hepatotoxicity risk at doses above 10 mg/kg/day, drug interactions through CYP induction particularly with calcineurin inhibitors post-transplant), maralixibat records (ileal bile acid transport inhibitor for ALGS-associated pruritus — approved dosing per weight band, dose escalation schedule, GI adverse effect monitoring including diarrhea and abdominal pain, fecal bile acid increase confirmation, clinical scratch score and pruritus assessments at each monitoring visit), cholestyramine and other sequestrant records (bile acid sequestrant dosing, compliance with unpalatable formulation, fat-soluble vitamin depletion acceleration from sequestrant use requiring supplementation intensification), and fat-soluble vitamin supplementation records (vitamins A, D, E, and K level monitoring — target 25-hydroxyvitamin D above 30 ng/mL, vitamin A retinol level monitoring for toxicity at high supplementation doses, vitamin E level and vitamin E-to-lipid ratio in hypercholesterolemic patients, PT/INR for vitamin K sufficiency) at 1-minute intervals during clinical hours. Alert immediately — maralixibat dosing platform failures for a 4-year-old with ALGS whose pruritus has been so severe that she scratches through the night causing skin breakdown and sleep deprivation compromising neurodevelopment — where the dosing platform must maintain the escalation schedule and response monitoring records that guide the pediatric gastroenterologist's assessment of whether the current maralixibat dose has reached the therapeutic threshold or requires escalation.
Neurovascular Surveillance — Intracranial Aneurysm and Moyamoya Screening
Monitor brain MRI and MRA records (screening MRI and MRA for intracranial aneurysms and moyamoya vascular changes — intracranial aneurysm location, size, morphology on MRA; moyamoya collateral vessel pattern; microhemorrhage on susceptibility-weighted imaging; surveillance interval documentation — annual or biennial MRI/MRA depending on prior findings and risk factors), CT angiography records (CT angiography for cases where MRA is indeterminate for small aneurysms or moyamoya vessel irregularity — slice thickness, contrast protocol, bone subtraction for posterior fossa aneurysm assessment), catheter cerebral angiography records (diagnostic angiography for definitive characterization of intracranial aneurysms identified on MRA — aneurysm dome, neck, and parent vessel anatomy for treatment planning; moyamoya staging and collateral characterization; pre-intervention angiographic planning), neurosurgery and neurointerventional records (aneurysm treatment — endovascular coiling, flow diverter, surgical clipping; moyamoya revascularization — pial synangiosis, encephaloduroarteriosynangiosis; post-intervention surveillance angiography), and stroke and intracranial hemorrhage acute management records (acute ischemic stroke secondary to moyamoya or aneurysmal thromboembolism; subarachnoid hemorrhage from aneurysm rupture — emergency evaluation, neurocritical care, vascular neurosurgery activation) at 1-minute intervals during imaging hours. Alert immediately — neurovascular MRI/MRA platform failures during the annual surveillance study of a 12-year-old with JAG1-positive ALGS who had an MRA three years ago showing a 3 mm anterior communicating artery irregularity of uncertain significance delay the follow-up study that determines whether the irregularity has grown toward the 5 mm threshold that generally prompts intervention, or has been stable — a determination that carries life-or-death implications for a child at 14% lifetime risk of intracranial hemorrhage.
Pediatric Cardiology — Congenital Cardiac Defect Management
Monitor echocardiography records (serial echocardiographic assessment of peripheral pulmonary stenosis — bilateral branch pulmonary artery stenosis, Doppler gradient across stenotic segments, right ventricular pressure estimation, right ventricular hypertrophy and function; tetralogy of Fallot anatomy documentation — VSD size and alignment, right ventricular outflow tract obstruction, pulmonary annulus z-score, aortic override; other structural defects), cardiac catheterization records (hemodynamic assessment of peripheral pulmonary stenosis severity — right ventricular to aortic pressure ratio; balloon pulmonary arterioplasty for branch pulmonary stenosis; pulmonary artery stent placement for severe peripheral stenosis), cardiac surgery records (tetralogy of Fallot repair — timing relative to pulmonary artery anatomy and right ventricular pressure; pulmonary artery reconstruction; ALGS-specific surgical risk considerations including hepatic synthetic function status, coagulopathy from vitamin K deficiency, and concurrent liver disease management in the perioperative period), and cardiac surveillance records (post-repair echocardiographic surveillance for residual pulmonary stenosis, pulmonary regurgitation following tetralogy repair, branch pulmonary artery restenosis, right ventricular function) at 1-minute intervals during clinical hours. Alert immediately — pediatric echocardiography platform failures during the neonatal evaluation of an infant with ALGS who has clinical features suggesting right ventricular outflow tract obstruction delay the echocardiographic characterization that distinguishes severe peripheral pulmonary stenosis requiring urgent catheter intervention from milder pulmonary stenosis compatible with watchful waiting while cholestasis management is optimized.
Hepatic Transplantation — Evaluation, Listing, and Post-Transplant Management
Monitor PELD/MELD score tracking records (ALGS-specific PELD calculation considerations — growth failure, albumin, bilirubin, PT/INR, age — PELD variance application documentation for ALGS patients whose disease severity is underestimated by standard PELD formula; UNOS policy exception documentation; listing status updates with PELD reassessment interval), pre-transplant cardiac evaluation records (cardiac evaluation for ALGS patients with concurrent congenital heart disease requiring liver transplantation — timing of cardiac repair relative to liver transplantation, staged repair-then-transplant versus combined liver transplant with concurrent cardiac repair, cardioanesthesia consultation), living donor evaluation records (parent as living liver donor — evaluation of parent who may carry the same JAG1 variant and have subclinical ALGS precluding donation; sibling donor evaluation; directed donation documentation), post-transplant immunosuppression records (tacrolimus and mycophenolate mofetil initiation, tacrolimus trough level monitoring at post-transplant intervals, acute rejection surveillance with liver biopsy protocol, calcineurin inhibitor nephrotoxicity monitoring in ALGS patients with pre-existing renal disease), and post-transplant renal surveillance records (ALGS renal disease progression monitoring post-transplant — creatinine, GFR, urinalysis, renal ultrasound for patients with pre-transplant renal abnormalities; calcineurin inhibitor nephrotoxicity monitoring; renovascular hypertension surveillance) at 1-minute intervals during clinical hours, 24/7 for organ allocation and transplant coordination platforms. Alert immediately — transplant coordination platform failures that interrupt organ acceptance decision-making for an 18-month-old with ALGS and end-stage liver disease with PELD score 32 — when the organ allocation platform must communicate the donor offer, organ quality assessment, and acceptance or decline decision within the offer response window — represent a potentially irreversible consequence of platform unavailability during the brief window in which organ acceptance can be confirmed for a critically ill toddler on the transplant waiting list.
Nephrology — Renal Disease Surveillance and Management
Monitor renal function surveillance records (annual serum creatinine and calculated GFR, urinalysis for proteinuria and hematuria, urine protein-to-creatinine ratio for early glomerular disease detection, renal ultrasound for cortical cysts and renovascular anatomy), renovascular hypertension records (blood pressure monitoring including ambulatory blood pressure monitoring for hypertension, renal Doppler for renovascular stenosis screening, catheter renal angiography for renovascular stenosis characterization, renal artery angioplasty and stenting records), renal tubular acidosis records (bicarbonate supplementation dosing and serum bicarbonate monitoring, urinary pH and anion gap documentation), and renal genetics records (NOTCH2-specific renal phenotype documentation — focal segmental glomerulosclerosis biopsy findings, nephrotic syndrome management including angiotensin pathway blockade) at 1-minute intervals during clinical hours.
Authentication and Clinical Identity
Monitor authentication at 1-minute intervals, 24/7. ALGS management coordinates across genetics (JAG1/NOTCH2 diagnosis, prenatal testing, cascade screening), pediatric hepatology (cholestasis, pruritus, nutrition, transplant triage), pediatric cardiology and cardiac surgery (congenital cardiac defect management), hepatic transplantation (organ allocation, surgical transplantation, post-transplant immunosuppression), neurology and neurovascular imaging (intracranial aneurysm and moyamoya surveillance), nephrology (renal disease management), and ophthalmology (slit-lamp assessment, visual surveillance) — authentication failures block every team member required to execute the multisystem surveillance, hepatic transplantation coordination, and neurovascular stroke prevention that define ALGS care.
SSL Certificates
Monitor SSL certificate expiry across all genetic testing platforms, pediatric hepatology portals, neurovascular MRI/MRA scheduling systems, transplant coordination platforms, cardiac surgery portals, nephrology surveillance systems, and ALGS registry platforms. Certificate errors disrupt transplant organ allocation communication (most critically), neurovascular imaging scheduling, and genetic testing result delivery.
HIPAA and Pediatric Multisystem Rare Disease Privacy Considerations
Alagille Syndrome technology platforms handle sensitive PHI spanning from prenatal diagnosis through adulthood, including JAG1 and NOTCH2 molecular genetic testing with heritable variant implications for parents, siblings, and future children (GINA protections for genetic information), neonatal liver disease records that may intersect with child protective services contexts where jaundice and failure-to-thrive in infancy require diagnostic differentiation from neglect, hepatic transplantation records, neurovascular surveillance imaging reports documenting intracranial aneurysm risk, congenital cardiac surgical records, and post-transplant immunosuppression records. The combination of pediatric onset, multisystem disease, and heritable genetics creates complex privacy challenges — including parental access rights to minor records, the disclosure of parental carrier status discovered through cascade testing, and the management of health information across the pediatric-to-adult care transition. For transplant coordination platforms — where unavailability during an organ offer acceptance window may result in organ decline for a critically ill child with end-stage liver disease — availability monitoring provides operational documentation relevant to HIPAA Security Rule compliance and the life-saving urgency of transplant coordination platform continuity.
Alerting Strategy for Alagille Syndrome Tech Platforms
Immediate 24/7 alerting for hepatic transplant coordination platforms: ALGS organ allocation offers, acceptance decisions, and transplant coordination events occur at all hours. There is no acceptable window of unavailability for organ offer communication and acceptance platforms.
Immediate clinical-hours alerting for pediatric hepatology platforms: Neonatal cholestasis workup, maralixibat dosing and monitoring, ursodeoxycholic acid management, and fat-soluble vitamin level monitoring.
Immediate imaging-hours alerting for neurovascular MRI/MRA platforms: Annual intracranial aneurysm and moyamoya surveillance for all ALGS patients — the 14% intracranial hemorrhage risk makes neurovascular surveillance platform availability a patient safety imperative.
Immediate laboratory-hours alerting for JAG1 and NOTCH2 genetic testing platforms: Molecular diagnosis and chromosomal microarray for 20p12 deletion cannot fail when results distinguish ALGS from biliary atresia requiring time-sensitive surgical intervention.
Immediate clinical-hours alerting for pediatric cardiology platforms: Echocardiographic assessment of peripheral pulmonary stenosis severity in neonates and serial cardiac surveillance for repaired tetralogy of Fallot.
Sustained-failure alert (10–15 minutes): Nephrology surveillance platforms, ophthalmology ALGS screening platforms, ALGS genetic counseling record systems, ALGS patient registry platforms.
30-day advance warning: SSL certificates across all domains.
Vigilmon's multi-region monitoring confirms ALGS platform availability from the geographies where pediatric hepatology and liver transplant programs, ALGS specialty centers, JAG1 molecular genetic testing laboratories, neurovascular surgical programs, and pediatric cardiac surgery programs concentrate.
Status Page for Alagille Syndrome Care Team Communication
A real-time status page gives pediatric hepatologists managing maralixibat titration and transplant triage for cholestatic ALGS patients, cardiac surgeons coordinating tetralogy of Fallot repair timing relative to liver disease severity, hepatic transplant coordinators tracking PELD scores and organ offers, neurovascular radiologists interpreting annual MRA for intracranial aneurysm surveillance, molecular geneticists delivering JAG1 sequencing results distinguishing ALGS from biliary atresia, and nephrologists managing renal disease in post-transplant ALGS patients immediate platform visibility without requiring inbound IT support contact.
Include the status page URL in ALGS hepatic transplant organ offer response protocols, neurovascular hemorrhage emergency response workflows, and genetic testing result delivery contingency procedures.
Vigilmon Setup for Alagille Syndrome Tech Platforms
A practical starting configuration:
| Monitor | Check Interval | Alert Channel | |---------|----------------|---------------| | Authentication | 1 min | Slack + PagerDuty (24/7) | | Hepatic transplant coordination (organ offer and allocation) | 1 min | Slack + PagerDuty (24/7) | | JAG1 / NOTCH2 sequencing and chromosomal microarray (20p12) | 1 min | Slack + PagerDuty (lab hours) | | Family cascade genetic testing and prenatal diagnosis | 1 min | Slack + PagerDuty (lab hours) | | Neonatal cholestasis workup and hepatology | 1 min | Slack + PagerDuty (clinical hours) | | Maralixibat dosing and pruritus response monitoring | 1 min | Slack + PagerDuty (clinical hours) | | Fat-soluble vitamin level monitoring (A, D, E, K) | 1 min | Slack + PagerDuty (lab hours) | | Neurovascular MRI/MRA (intracranial aneurysm surveillance) | 1 min | Slack + PagerDuty (imaging hours) | | Pediatric echocardiography (pulmonary stenosis, TOF) | 1 min | Slack + PagerDuty (clinical hours) | | Post-transplant immunosuppression monitoring (tacrolimus levels) | 1 min | Slack + PagerDuty (clinical hours) | | Renal surveillance (GFR, renovascular hypertension) | 2 min | Slack + PagerDuty (clinical hours) | | Ophthalmology slit-lamp and visual field surveillance | 2 min | Slack (business hours) | | ALGS patient registry and multisystem tracking | 2 min | Slack (business hours) | | SSL: all domains | Daily | Email (30-day warning) |
Getting started:
- Create a free account at vigilmon.online
- Add authentication endpoints at 1-minute intervals with 24/7 alerting
- Configure hepatic transplant coordination platforms with immediate 24/7 alerting — this is the highest-priority platform for ALGS patients awaiting liver transplantation
- Add JAG1 and NOTCH2 sequencing and chromosomal microarray platforms with immediate laboratory-hours alerting
- Configure family cascade genetic testing and prenatal diagnosis platforms with immediate laboratory-hours alerting
- Add neonatal cholestasis workup and pediatric hepatology platforms with immediate clinical-hours alerting
- Configure maralixibat dosing and pruritus monitoring platforms with immediate clinical-hours alerting
- Add fat-soluble vitamin level monitoring laboratory platforms with immediate laboratory-hours alerting
- Configure neurovascular MRI/MRA surveillance platforms with immediate imaging-hours alerting
- Add pediatric echocardiography platforms with immediate clinical-hours alerting for neonatal cardiac assessment
- Configure post-transplant immunosuppression monitoring platforms with immediate clinical-hours alerting
- Add renal surveillance platforms with sustained-failure clinical-hours alerting
- Configure ophthalmology ALGS surveillance platforms with sustained-failure business-hours alerting
- Add ALGS patient registry with sustained-failure alerting during business hours
- Enable SSL certificate monitoring across all genetic testing, hepatology, transplant coordination, neurovascular imaging, and cardiac surgery platforms
- Add the status page URL to transplant organ offer response protocols, neurovascular hemorrhage emergency workflows, and cholestasis workup contingency procedures
Conclusion
Alagille Syndrome technology platforms are embedded in clinical decisions where hepatic transplant coordination platform availability in the middle of the night when a 22-month-old with JAG1-positive ALGS and end-stage biliary cirrhosis — with a PELD score of 35 and progressive ascites, growth failure with weight-for-age below the third percentile, recurrent variceal bleeding from portal hypertension, and worsening coagulopathy with INR persistently above 2.0 — is offered a deceased donor pediatric liver from an ABO-compatible 4-year-old donor whose family authorized donation following a traumatic brain injury — when the transplant coordinator must receive the organ offer, assess donor quality parameters including cold ischemia time feasibility, confirm the recipient's clinical suitability for urgent transplantation with the hepatology fellow, activate the cardiac anesthesia team for pre-induction management of this child's concurrent severe right ventricular outflow tract obstruction from peripheral pulmonary stenosis, confirm the family's availability for emergency hospitalization, and transmit the organ acceptance to the organ procurement organization within the response window that determines whether this organ goes to this critically ill toddler or to the next patient on the allocation list — cannot be disrupted by transplant coordination platform failures that allow the organ offer window to close on a child whose PELD score documents immediate mortality risk without transplantation; where JAG1 genetic testing platform availability during the evaluation of a 5-week-old with persistent jaundice and direct bilirubin of 4.2 mg/dL cannot be disrupted by sequencing platform failures that delay the molecular result that distinguishes JAG1-positive ALGS — in which Kasai hepatoportoenterostomy is not indicated and would expose the infant to a major abdominal operation that will not address the underlying intrahepatic bile duct paucity — from biliary atresia — in which Kasai hepatoportoenterostomy within 60 days of life is the only non-transplant intervention available to establish bile flow before cirrhosis becomes irreversible — a diagnostic distinction where platform availability determines whether a family receives the correct guidance before the surgical decision window closes irreversibly; and where neurovascular MRI/MRA platform availability for the annual intracranial vascular surveillance of a 9-year-old with ALGS — whose father experienced a subarachnoid hemorrhage from a ruptured intracranial aneurysm at age 31, whose prior MRA three years ago showed a 2 mm anterior communicating artery irregularity, and who has been asymptomatic with normal neurological examination — cannot be disrupted by imaging platform failures that delay the surveillance study which may identify growth of the anterior communicating irregularity toward the size threshold that prompts neurointerventional consultation and potentially preventive endovascular treatment of an aneurysm not yet ruptured. A transplant coordination platform unavailable during an organ offer window for a critically ill toddler with end-stage ALGS liver disease, a JAG1 genetic testing platform unavailable when the result distinguishes Kasai candidacy from ALGS management in a 5-week-old, a neurovascular imaging platform unavailable when an intracranial aneurysm surveillance scan may identify treatable disease before hemorrhage — these are not IT incidents. They are clinical disruptions in the management of a multisystem heritable developmental syndrome where platform reliability is a direct determinant of transplant organ utilization, surgical decision correctness, and neurovascular stroke prevention in children whose multiorgan disease makes technology coordination across hepatology, cardiac surgery, transplant medicine, and neurovascular disciplines the operational foundation of survival and functional outcome.
Uptime monitoring gives Alagille Syndrome tech teams the detection capability to identify failures within seconds, trigger immediate clinical downtime procedures, and demonstrate to pediatric hepatology and liver transplant programs, JAG1 molecular genetic testing laboratories, neurovascular surgical and interventional programs, pediatric cardiac surgery centers, and compliance auditors that platform operational reliability matches the organ allocation response speed, neonatal cholestasis diagnostic urgency, neurovascular hemorrhage prevention precision, and multisystem surveillance intensity of modern ALGS care.
Start monitoring your Alagille Syndrome care tech platform for free at vigilmon.online — HTTP/HTTPS monitoring, multi-region consensus alerting, SSL certificate monitoring, automatic status page, Slack and webhook alerts. No agent required. No credit card.
Tags: #monitoring #Alagille #ALGS #JAG1 #NOTCH2 #cholestasis #bileduct #paucity #transplant #maralixibat #UDCA #peripheralpulmonarystenosis #tetralogyofFallot #intracranialaneurysm #moyamoya #neurovascular #PELD #pediatric #rare #genetic #hepatology #HIPAA #healthtech #digitalhealth #uptime #sre